Mutation burden and other molecular markers of prognosis in the QUASAR2 clinical trial of colorectal cancer treated with curative intent
Several relatively large studies have assessed molecular indicators of colorectal cancer (CRC) prognosis, but most analyses have been restricted to a handful of markers.
In stage II/III CRCs from the QUASAR2 clinical trial and from an Australian community-based series, we assessed gene panels for somatic driver mutations and overall mutation burden. We determined molecular pathways of tumorigenesis, and analysed associations with treatment respo...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 368.1KB)
- Publisher copy:
- Copyright holder:
- Church et al
- Copyright date:
- © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record